EP0868179A4 - New use for losartan - Google Patents

New use for losartan

Info

Publication number
EP0868179A4
EP0868179A4 EP96944328A EP96944328A EP0868179A4 EP 0868179 A4 EP0868179 A4 EP 0868179A4 EP 96944328 A EP96944328 A EP 96944328A EP 96944328 A EP96944328 A EP 96944328A EP 0868179 A4 EP0868179 A4 EP 0868179A4
Authority
EP
European Patent Office
Prior art keywords
losartan
new use
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96944328A
Other languages
German (de)
French (fr)
Other versions
EP0868179A1 (en
Inventor
Sheila M Cohen
Jeffrey G Werrmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9603376.6A external-priority patent/GB9603376D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0868179A1 publication Critical patent/EP0868179A1/en
Publication of EP0868179A4 publication Critical patent/EP0868179A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP96944328A 1995-12-12 1996-12-09 New use for losartan Withdrawn EP0868179A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US875795P 1995-12-12 1995-12-12
GB9603376 1996-02-16
GBGB9603376.6A GB9603376D0 (en) 1996-02-16 1996-02-16 New use for Iosartan
PCT/US1996/019781 WO1997021436A1 (en) 1995-12-12 1996-12-09 New use for losartan
US8757 1998-01-19

Publications (2)

Publication Number Publication Date
EP0868179A1 EP0868179A1 (en) 1998-10-07
EP0868179A4 true EP0868179A4 (en) 2002-01-30

Family

ID=26308746

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96944328A Withdrawn EP0868179A4 (en) 1995-12-12 1996-12-09 New use for losartan

Country Status (4)

Country Link
EP (1) EP0868179A4 (en)
JP (1) JP2000501736A (en)
CA (1) CA2238975A1 (en)
WO (1) WO1997021436A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0855392A3 (en) 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Five-membered heterocycles having biphenylsulphonyl substituents, processes for the preparation thereof, their use as medicaments or diagnostic agent and medicaments containing them
IT1295405B1 (en) 1997-09-30 1999-05-12 Merck Sharp & Dohme Italia S P USE OF AN ANGIOTENSIN II RECEPTORAL ANTAGONIST FOR DRUG PREPARATION TO INCREASE THE SURVIVAL RATE OF
PL197164B1 (en) * 1997-10-17 2008-03-31 Ark Therapeutics Ltd The use of inhibitors of the renin-angiotensin system
GB2337701A (en) * 1998-05-26 1999-12-01 United Medical And Dental Schools Of Guys St Thomas Hospitals Treatment of ischemia with an angiotensin II antagonist
CN101011390A (en) 1999-01-26 2007-08-08 诺瓦提斯公司 Use of angiotensin II receptor antagonists for treating acute myocardial infarction
EP1438027A1 (en) * 2001-10-25 2004-07-21 DepoMed, Inc. Methods of treatment using a gastric retained losartan dosage
US7906145B2 (en) 2002-04-09 2011-03-15 Flamel Technologies Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
JP2006511616A (en) 2002-11-13 2006-04-06 カイロン コーポレイション Methods for treating cancer and related methods
AU2005216904B2 (en) 2004-02-20 2010-11-25 Novartis Vaccines And Diagnostics, Inc. Modulation of inflammatory and metastatic processes
FR2882260A1 (en) * 2005-02-21 2006-08-25 Flamel Technologies Sa MULTIMICROPARTICULAR ORAL PHARMACEUTICAL FORM WITH MODIFIED RELEASE OF ANTAGONISTS OF ANGIOTENSIN II RECEPTORS
US20090123536A1 (en) * 2005-02-21 2009-05-14 Flamel Technologies, S.A. Oral Pharmaceutical Form of Losartan
FR2884145A1 (en) * 2005-04-06 2006-10-13 Flamel Technologies Sa Use of a controlled release losartan oral dosage form, to decrease the inter individual gap of standard deviation of maximum concentration of the losartan, independent of administration of losartan before or after the meals
KR101319122B1 (en) 2005-05-13 2013-10-23 노파르티스 아게 Methods for treating drug resistant cancer
US20120095067A1 (en) * 2009-06-25 2012-04-19 Jin Yang Pharm. Co., Ltd. Pharmaceutical composition containing carboxylosartan and a production method therefor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565485A (en) * 1993-03-19 1996-10-15 Merck & Co., Inc. Biphenyl compounds useful or endothelin antagonists
US5538991A (en) * 1994-09-14 1996-07-23 Merck & Co., Inc. Endothelin antagonists bearing 5-membered heterocyclic amides

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CAPASSO ET AL.: "Efficacy of ACE inhibition and AT1 receptor blockade on cardiac pump performance after myocardial infarction in rats", J. CARDIOVASC. PHARMACOL., vol. 23, 1994, pages 584 - 593, XP001033935 *
FLEETWOOD G ET AL: "INVOLVEMENT OF THE RENIN ANGIOTENSIN SYSTEM IN ISCHEMIC DAMAGE AND REPERFUSION ARRHYTHMIAS IN THE ISOLATED PERFUSED RAT HEART", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, vol. 17, no. 3, 1991, pages 351 - 356, XP001029360, ISSN: 0160-2446 *
IZUMI HISAKO ET AL: "Effects of BIBR-277, an angiotensin II type 1 receptor antagonist, on stunned myocardium in dogs.", CORONARY ARTERY DISEASE, vol. 7, no. 10, 1996, pages 775 - 779, XP001033778, ISSN: 0954-6928 *
SCHIEFFER ET AL.: "Comparative effects of chronic ACE inhibition and AII type1 receptor blockade on cardiac remodeling after myocardial infarction in the rat", CIRCULATION, vol. 89, 1994, pages 2273 - 2282, XP001033870 *
See also references of WO9721436A1 *
WERRMANN JEFFREY G ET AL: "Comparison of effects of angiotensin-converting enzyme inhibition with those of angiotensin II receptor antagonism on functional and metabolic recovery in postischemic working rat heart as studied by (31P) nuclear magnetic resonance.", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, vol. 24, no. 4, 1994, pages 573 - 586, XP001029379, ISSN: 0160-2446 *
YOSHIYAMA ET AL.: "cardioprotective effect of the AII type 1 receptor antagonisr TCV-116 on ischemia-reperfusion injury", AMERICAN HEART JOURNAL, vol. 128, 1994, pages 1-6, XP001029664 *
YOSHIYAMA MINORU ET AL: "Protective effect of pretreatment with angiotensin II type I receptor antagonist on the ischemia-reperfused myocardium.", CIRCULATION, vol. 88, no. 4 PART 2, 1993, 66th Scientific Sessions of the American Heart Association;Atlanta, Georgia, USA; November 8-11, 1993, pages I474, XP001029391, ISSN: 0009-7322 *
ZWEIER JAY L ET AL: "Angiotensin II receptor blockade decreases neutrophil-mediated injury in the postischemic heart.", FASEB JOURNAL, vol. 9, no. 4, 1995, Experimental Biology 95, Part II;Atlanta, Georgia, USA; April 9-13, 1995, pages A844, XP001029375, ISSN: 0892-6638 *

Also Published As

Publication number Publication date
AU1416497A (en) 1997-07-03
EP0868179A1 (en) 1998-10-07
AU704841B2 (en) 1999-05-06
CA2238975A1 (en) 1997-06-19
WO1997021436A1 (en) 1997-06-19
JP2000501736A (en) 2000-02-15

Similar Documents

Publication Publication Date Title
PL324869A1 (en) Benzimidazole compounds
HU9600255D0 (en) New compounds
EP0868179A4 (en) New use for losartan
GB9500691D0 (en) Compounds
GB9504910D0 (en) Compounds
GB9505538D0 (en) New compounds
GB9508637D0 (en) New use
GB2308509B (en) Services-connections for trailer-vehicles
GB9504948D0 (en) Compounds
GB2308393B (en) Windshelter for sun-bathing
GB9502540D0 (en) Compounds
GB2298174B (en) Services-connections for trailer-vehicles
ZA963484B (en) New use
GB9516136D0 (en) New Use
GB9505071D0 (en) Use
GB9519905D0 (en) Use
GB9520121D0 (en) Use
GB9520119D0 (en) Use
GB9519915D0 (en) Use
GB9503206D0 (en) Novel use
GB9515843D0 (en) Benzimidazole compounds
GB9506703D0 (en) Compounds
GB9526630D0 (en) Compounds
GB9518487D0 (en) Compounds
GB9506168D0 (en) Compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980713

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20011217

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20020405

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040422